Stock Research for GERN


Featured Broker: Ally Invest

Get the due diligence for another stock.


GERN Stock Chart & Research Data

The GERN chart settings shown below allow you to select time intervals of 1 min, 30 mins, an hour or by day - week - month. There is also the ability to change the GERN chart style to candles, hollow candles, bars, lines or add various indicators. You can even add a symbol and compare history.


GERN Due diligence Resources & Stock Charts

The GERN stock resources shown below were gathered to cut back on time by allowing you to visit multiple sites at once. For your convenience each link clicked will open in a window. In addition to the individual links there is a button at the bottom that will allow you to open all the links at the same time. Note opening all links at once may not work with all browsers. Some browsers block multiple windows, to resolve this please allow that site to use pop-ups.

The Four Most Popular Resources

CNN View GERN Detailed Price Forecast - CNN Money CNN View GERN Detailed Summary - Google Finance
Yahoo View GERN Detailed Summary - Yahoo! Finance Zacks View GERN Stock Research & Analysis -

Stock Analysis

TradeIdeas View GERN Trends & Analysis - Trade-Ideas Barrons View GERN Major Holders - Barrons
NASDAQ View GERN Call Transcripts - NASDAQ Seeking View GERN Breaking News & Analysis - Seeking Alpha
Spotlight View GERN Annual Report - OTC Report View GERN OTC Short Report -
TradeKing View GERN Fundamentals - TradeKing Charts View GERN SEC Filings - Bar Chart
WSJ View Historical Prices for GERN - The WSJ Morningstar View Performance/Total Return for GERN - Morningstar
MarketWatch View the Analyst Estimates for GERN - MarketWatch CNBC View the Earnings History for GERN - CNBC
StockMarketWatch View the GERN Earnings - StockMarketWatch MacroAxis View GERN Buy or Sell Recommendations - MacroAxis
Bullish View the GERN Bullish Patterns - American Bulls Short Pains View GERN Short Pain Metrics -

Social Media Mentions

StockTwits View GERN Stock Mentions - StockTwits PennyStocks View GERN Stock Mentions - PennyStockTweets
Twitter View GERN Stock Mentions - Twitter Invest Hub View GERN Investment Forum News - Investor Hub
Yahoo View GERN Stock Mentions - Yahoo! Message Board Seeking Alpha View GERN Stock Mentions - Seeking Alpha

Financial & Transaction Holdings

SECform4 View Insider Transactions for GERN - Insider Cow View Insider Transactions for GERN - Insider Cow
CNBC View GERN Major Holdings Summary - CNBC OTC Markets View Insider Disclosure for GERN - OTC Markets
Yahoo View Insider Transactions for GERN - Yahoo! Finance NASDAQ View Institutional Holdings for GERN - NASDAQ

Stock Charts

FinViz View GERN Stock Insight & Charts - StockCharts View GERN Investment Charts -
BarChart View GERN Stock Overview & Charts - BarChart Trading View View GERN User Generated Charts - Trading View

Latest Financial News for GERN

Why Geron Corporation Stock Is Heating Up
Posted on Wednesday May 23, 2018

Geron's stock is blasting higher this week, but the exact reason isn't clear.

Today's Research Reports on Trending Tickers: Geron and Forward Pharma
Posted on Wednesday May 23, 2018

NEW YORK, NY / ACCESSWIRE / May 23, 2018 / U.S. markets fell Tuesday on geopolitical concerns after President Trump stated he was not happy with the current U.S. – China trade talks. The Dow Jones Industrial ...

MARKETS: Here's why stocks are surging and how it could all go wrong
Posted on Monday May 21, 2018

Yahoo Finance's Jared Blikre joins Seana Smith from the floor of the New York Stock Exchange to discuss the latest market moves.

Geron Announces Oral Presentation at European Hematology Association Congress
Posted on Thursday May 17, 2018

Geron Corporation (GERN) today announced that an abstract describing clinical data regarding the telomerase inhibitor imetelstat has been selected for an oral presentation at the 23rd Congress of the European Hematology Association (EHA) to be held in Stockholm, Sweden from June 14-17, 2018. The abstract contains updated data (as of January 2018) from the first 32 patients enrolled in Part 1 of IMerge, the ongoing Phase 2/3 clinical trial of imetelstat in patients with lower risk myelodysplastic syndromes (MDS) being conducted by Janssen Research & Development, LLC.

Enter a stock symbol to view the stock details.